modifications (12% vs. 40%, p=0.53), dose omissions (19% vs. 33%, p=0.31), and showed higher KN522 completion rates (81% vs. 53%, p=0.06).Conclusions:Our findings indicate a comparable pCR rate between Hispanic and non-Hispanic patients with early-stage TNBC receiving KN522 therapy....
KEYNOTE-522 (ClinicalTrials.gov, NCT03036488), is a randomized, double-blind Phase 3 trial. The dual primary endpoints were pCR rate, defined as pathological stage ypT0/Tis ypN0 at the time of definitive surgery, and event-free sur...
Dual primary endpoints are pCR rate (ypT0/Tis ypN0) and EFS. Secondary endpoints include pCR rate (ypT0 ypN0) in all pts and in those with PD-L1+ tumors (ie, PD-L1 staining in ≥ 1% tumor cells or stroma), pCR rate (ypT0/Tis ypN0) in pts with PD-L1+ tumors, EFS in ...
Latest Conference Coverage Sintilimab Plus Chemoradiotherapy Improves pCR Rate in Resectable, Locally Advanced ESCC Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer Trastuzumab Combo Shows Numerical Survival Benefit in Gastric/GEJ Cancer Telotristat...
Conclusions Addition of pembro to neoadjuvant chemo significantly increased the pCR rate in pts with early TNBC. Neoadjuvant pembro + chemo followed by adjuvant pembro showed a favorable trend in EFS. AEs were consistent with the known safety profiles of each agent. Clinical trial identification NCT...
In prior interim analyses, pembro + chemo showed a significant improvement in pCR and a favorable trend in EFS. We present results from a prespecified interim analysis of KEYNOTE-522. Methods Pts with previously untreated, non-metastatic, centrally confirmed TNBC (stage T1c N1-2 or T2-4 N0-...
In the next slide, you can see that the primary end point at the interim analysis shows that the pathologic complete response rate is almost 14% better in patients who received pembrolizumab. Patients who achieve a pCR tend to have better outcomes. In this study, event-free survival is shown...
In addition to the dual primary end points of pCR rate and EFS, secondary end points of the study are overall survival and safety. “While significant advancements have been made in the treatment of ER-positive, HER2-negative breast cancer, people diagnosed with high-risk disease as...
Key secondary endpoints include pCR and mPR. The study enrolled 786 patients who were randomly assigned (1:1) to receive either: KEYTRUDA (200 mg intravenously [IV] every three weeks [Q3W] for up to four cycles) plus chemoth...
之前的Keynote522研究告诉我们PD-1单抗用于早期高危三阴型乳腺癌患者,新辅助治疗可提高pCR率(1),辅助治疗延长了无事件生存期(2),OS显示获益趋势。那么,它是否在晚期三阴乳腺癌中可以占有一席之地呢?最近发表于《新英格兰医学杂志》的结果表明,一线治疗局部复发不可手术或转移性三阴性乳腺癌患者,在PD-L1阳性综合...